AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
copanlisib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| phosphatidylinositol 3-kinase inhibitors, antineoplastics | 5256 | 1032568-63-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFkB signaling in lymphoma cell lines.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 6.43 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 10.34 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.42 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 25.20 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.853 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 44.361 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 2.618 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.846 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 32.980 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 40.230 | % | High | 1 |
| herg | hERG pIC50 | 4.612 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.245 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 19.364 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 23.190 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK9,CSF1R,DDR1,FLT3,GRK2,ITK,MAP3K21,MAPK7,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2 | 20 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,FLT3,MAP3K21,MAPK7,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2 | 12 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 18.323 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 8.222 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 26.230 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 23.442 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 45.520 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 4.613 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 60.110 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 21.560 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 10.069 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 14, 2017 | FDA | BAYER HEALTHCARE PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Metastases to muscle | 66.66 | 52.09 | 9 | 573 | 376 | 110588341 |
| Metastases to retroperitoneum | 65.71 | 52.09 | 9 | 573 | 419 | 110588298 |
| Cytopenia | 62.88 | 52.09 | 17 | 565 | 30099 | 110558618 |
| Pyrexia | 62.57 | 52.09 | 45 | 537 | 898220 | 109690497 |
| Neutropenic sepsis | 62.54 | 52.09 | 17 | 565 | 30729 | 110557988 |
| Metastases to spleen | 59.60 | 52.09 | 9 | 573 | 835 | 110587882 |
| Metastases to bone marrow | 57.95 | 52.09 | 9 | 573 | 1005 | 110587712 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EM02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Phosphatidylinositol-3-kinase (Pi3K) inhibitors |
| FDA MoA | N0000175082 | Kinase Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50914 | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
Related Drugs by ATC class:
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Follicular lymphoma | indication | 55150002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.78 | acidic |
| pKa2 | 9.17 | Basic |
| pKa3 | 7.65 | Basic |
| pKa4 | 6.36 | Basic |
| pKa5 | 2.69 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | INHIBITOR | IC50 | 9.16 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Kinase | INHIBITOR | IC50 | 9.30 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Serine/threonine-protein kinase mTOR | Kinase | INHIBITOR | IC50 | 7.35 | IUPHAR | ||||
| Ras-related protein Rab-27A | Enzyme | Kd | 5.35 | CHEMBL | |||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Kinase | INHIBITOR | IC50 | 8.43 | SCIENTIFIC LITERATURE | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Kinase | INHIBITOR | IC50 | 8.19 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| WI6V529FZ9 | UNII |
| 1402152-13-9 | SECONDARY_CAS_RN |
| 1402152-46-8 | SECONDARY_CAS_RN |
| 4036879 | VANDF |
| C4049141 | UMLSCUI |
| CHEBI:173077 | CHEBI |
| CHEMBL3218576 | ChEMBL_ID |
| 135565596 | PUBCHEM_CID |
| DB12483 | DRUGBANK_ID |
| CHEMBL3545068 | ChEMBL_ID |
| D10797 | KEGG_DRUG |
| 9726 | INN_ID |
| C000589253 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7875 | IUPHAR_LIGAND_ID |
| 741057007 | SNOMEDCT_US |
| 763592006 | SNOMEDCT_US |
| 6E2 | PDB_CHEM_ID |
| d08659 | MMSL |
| 017343 | NDDF |
| 1945077 | RXNORM |
| WI6V529FZ9 | INXIGHT DRUGS |
Pharmaceutical products:
None